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Abstract
Background: The aim of this study was to evaluate epigenetic status of cyclin A1 in human papillomavirus-
associated cervical cancer. Y. Tokumaru et al., Cancer Res 64, 5982-7 (Sep 1, 2004)demonstrated in head
and neck squamous-cell cancer an inverse correlation between cyclin A1 promoter hypermethylation and
TP53 mutation. Human papillomavirus-associated cervical cancer, however, is deprived of TP53 function
by a different mechanism. Therefore, it was of interest to investigate the epigenetic alterations during
multistep cervical cancer development.
Methods: In this study, we performed duplex methylation-specific PCR and reverse transcriptase PCR on
several cervical cancer cell lines and microdissected cervical cancers. Furthermore, the incidence of cyclin
A1 methylation was studied in 43 samples of white blood cells, 25 normal cervices, and 24, 5 and 30 human
papillomavirus-associated premalignant, microinvasive and invasive cervical lesions, respectively.
Results: We demonstrated cyclin A1 methylation to be commonly found in cervical cancer, both in vitro
and in vivo, with its physiological role being to decrease gene expression. More important, this study
demonstrated that not only is cyclin A1 promoter hypermethylation strikingly common in cervical cancer,
but is also specific to the invasive phenotype in comparison with other histopathological stages during
multistep carcinogenesis. None of the normal cells and low-grade squamous intraepithelial lesions
exhibited methylation. In contrast, 36.6%, 60% and 93.3% of high-grade squamous intraepithelial lesions,
microinvasive and invasive cancers, respectively, showed methylation.
Conclusion: This methylation study indicated that cyclin A1 is a potential tumor marker for early diagnosis
of invasive cervical cancer.
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Background
Cervical cancer (CC) is an important health problem and
is a leading cause of cancer mortality worldwide in
women. [1] When exposed to and infected by one of the
high-risk human papillomaviruses (HPV), vulnerable cer-
vical epithelium may enter a complex multistep process
and develop an invasive carcinoma. [2-4] The spectrum of
histologic alterations during the intricate processes of
multistep carcinogenesis can be classified as premalignant
lesions, including low-grade and high-grade squamous
intraepithelial lesions (SILs), and malignant invasive cer-
vical cancers. [5] Despite its strong association with CC,
HPV infection alone is not sufficient for the cervical epi-
thelium to fully develop an invasive cervical cancer. Per-
sistent HPV infection contributes to the development of
SILs, with viral oncoproteins facilitating the dysregulation
of cellular proliferation and the apoptotic process. How-
ever, additional accumulation of mutations, as well as epi-
genetic alterations in the crucial oncogenes and tumor
suppressor genes, is required before these premalignant
lesions fully transform into invasive cancers. [6]
The aim of this study was to evaluate DNA methylation
status of cyclin A1 (CCNA1) in HPV-associated CC.
CCNA1, a second A-type cyclin, has been shown to be
essential for entry into metaphase of male meiosis I[7,8]
Consistent with this function, CCNA1 is highly expressed
in testis and hematopoietic progenitor cells, but is present
at low levels in most other tissues. [9] No phenotype other
than male infertility has been reported in mice lacking
CCNA1. [10] Surprisingly, several lines of evidence sug-
gest that CCNA1 may be a potential epithelial tumor sup-
pressor gene. First, the expression of CCNA1  has been
demonstrated to be downregulated in several cancers,
such as nasopharyngeal carcinoma and head and neck
squamous-cell cancer (HNSCC). [11-13] Second, CCNA1
plays an important role in DNA double-strand break
repair following radiation damage by activation of the
non-homologous end-joining process that confers DNA
stability. [14] Finally, the promoter, similar to several key
tumor suppressor genes, is frequently hypermethylated in
colon cancer and HNSCC. [13,15]
Expression of CCNA1 has been shown to be correlated
with the activation of TP53. In a HNSCC model, there is
an inverse relationship between CCNA1 promoter meth-
ylation and TP53 mutation status in HNSCC tissues. [13]
Similar to HNSCC, the majority of CC is of squamous cell
origin and its molecular carcinogenesis strongly correlates
with impaired TP53 function. [16-18] However, unlike
HNSCC, the functional loss of TP53 in CC is not ascribed
to gene mutation, but is processed by viral and host pro-
tein-protein interaction. CC is strongly associated with
infection by high-risk HPV types and its oncoprotein E6
has the ability to associate with and neutralize the func-
tion of TP53. [17,18] E6 binds to TP53 and catalyzes
multi-ubiquitination and degradation of TP53. Conse-
quently, the majority of CC cells have a wild-type TP53,
but the protein levels are decreased. Therefore, in compar-
ison with HNSCC, it was of interest to determine if
CCNA1 is methylated in HPV-associated squamous cell
CC.
Methods
Cell lines and tissue samples
SiHa and two HeLa CC cell lines from different sources
were grown in Dulbecco's modified Eagle's medium sup-
plemented with 10% fetal bovine serum. All three cells
were purchased from ATCC. SiHa, HeLa (S), and HeLa (K)
were grown and maintained in laboratories of Dr. Pong-
likitmongkol M, Mahidol University, Dr. Gutkind JS,
NIH, USA and Dr. Ruxrungthum K, Chulalongkorn Uni-
versity, respectively.
With approval of ethical committee, faculty of medicine,
Chulalongkorn university, normal cervical tissues, cancer
tissues and blood samples were obtained and prepared as
previously described. [19,20] Cervical tissues were
obtained by punch biopsy of lesions under direct visuali-
zation or under colposcopic examination. Specimens
were divided in two. The first sample was submitted to
routine histological examination, and the second was
reserved for DNA isolation. Blood samples were obtained
by venipuncture from CC patients and healthy blood
donors. All HPV-positive premalignant lesions were exfo-
liated cells, selected from routine cytological screening. In
brief, cervical cells were collected with a cervical sampler
(Digene Corporation, Gaithersburg, MD, USA) using the
cervical cytobrush technique, and were divided into three
parts. The first was reserved for routine cytological diagno-
sis. The second was tested for the presence of high-risk
HPV (types 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59,
and 68) DNA by Hybrid Capture 2 (Digene Corporation,
Gaithersburg, MD, USA). [21] In cases of positive high-
risk HPV and complete histological tissue evaluation, the
third part was subjected to CCNA1 methylation analysis.
DNA extraction was performed using Tris/SDS and protei-
nase K at 50°C overnight, followed by phenol/chloro-
form extraction and ethanol precipitation.
Cervical biopsy specimens and Papanicolaou smears were
examined and reviewed by at least two gynecologic
pathologists to ensure good quality control of the final
pathology results. All CCs contained 20–95% malignant
cells. The histological diagnoses distinguished among
normal epithelium, low-grade SILs, high-grade SILs,
microinvasive and invasive cancer. In case of invasive can-
cer, only those samples classified as squamous-cell lesions
were used for further analysis.BMC Cancer 2006, 6:55 http://www.biomedcentral.com/1471-2407/6/55
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Additional six OTC-embedded frozen CCs and five nor-
mal cervices, obtained from hysterectomy specimens,
were microdissected as previously described.22 Histologi-
cally normal epithelium, connective tissue and malignant
cells were subjected to CCNA1 methylation and expres-
sion studies.
HPV detection and typing
HPV L1, E6 gene amplification and dot blot hybridization
were performed as previously described[19,22,23] Briefly,
each L1 amplification reaction contained the L1 degener-
ate primers MY11 and MY09. The E6 reactions contained
WD72, WD66, WD154, WD67 and WD76. Both reactions
were used to amplify genomic DNA during 40 PCR cycles.
To analyze the amplicons for the presence of high-risk
HPV, we applied dot blot hybridization using the HPV
type-specific oligo probes, WD170, WD132, RR1, RR2,
WD103, WD165, WD, consensus L1, MY12/13, WD126,
WD128, MY16, WD133/134, MY14 and WD174. The
membranes were subjected to analysis by a phosphoim-
ager. Results for L1 and E6 dot blots were scored inde-
pendently. Duplicate filters were prepared for all
specimens.
Sodium bisulfite modification and duplex methylation-
specific PCR (MSP)
The DNA samples were subjected to bisulfite treatment.
[24,25] Briefly, 2 µg of genomic DNA was denatured with
NaOH (final concentration 0.2 M). Subsequently, 10 mM
hydroquinone and 3 M sodium bisulfite were added and
incubated at 50°C for 16 h. The modified DNA was then
purified using Wizard DNA purification resin (Promega,
Madison, WI, USA) followed by ethanol precipitation.
Duplex MSPs were performed to identify the CCNA1
methylation status of all samples. The duplex PCR mix-
tures contained 10× PCR buffer (Qiagen, Chuo-ku,
Tokyo), deoxynucleotide triphosphates (0.2 mM), prim-
ers CCNA1metF, CCNA1metR, CCNA1unmetF and
CCNA1unmetR (final concentration 0.4 µM each per
reaction) (Table 1), 1 U of HotStarTaq (Qiagen, Chuo-ku,
Tokyo) and bisulfited DNA (80 ng). The amplification
reaction was carried out for 30 cycles in a 2400 Perkin
Elmer thermal cycler. Then 10-µl aliquots of the PCR
products were stained with cyber green, run on an 8%
non-denaturing polyacrylamide gel. The band intensity
was visualized and measured by using a phosphoimager.
RNA preparation and analysis
Expression of CCNA1 in the CC cell lines was examined
by RT-PCR. Total RNA was extracted using the TRIZOL
reagent (Invitrogen, Singapore) according to the manufac-
turer's specifications and 5 µg of each sample was sub-
jected to cDNA synthesis using MMLV reverse
transcriptase (Fermentas, Hanover, MD, USA). PCR mix-
tures contained 10× PCR buffer, 0.2 mM dNTPs, 0.4 µM
each of primers CCNA1cDNAF and CNA1cDNAR, 1 U of
HotStartaq and 80 ng cDNA. GAPDH served as the inter-
nal control (Table 1). Aliquots of 10 µl of the PCR prod-
ucts were subjected to electrophoresis on a 2% agarose gel
stained with ethidium bromide on preparation, and were
visualized by a UV trans-illuminator.
Bisulfite genome sequence analysis
Some CCNA1 methylation-positive CCs were selected for
sequence analysis. The bisulfited DNAs were amplified
using CCNA1cloningF and CCNA1cloningR (Table 1).
The amplified fragments were cloned using the PGemT
easy vector and sequenced.
Results
The aim of this study was to determine if the CCNA1 pro-
moter is methylated in CC and to elucidate how the epi-
genetic alteration occurs during multistep CC
development. The experiments conducted comprised of:
first, establishment of CCNA1 MSP; second, identification
of the methylation status and correlation with expression
in CC cell lines, normal cervix and CC; and finally, inves-
tigation of the frequency of methylation in normal tissues,
high-risk HPV-associated low SILs, high SILs, microinva-
sive and invasive squamous cell CC.
Table 1: Oligonucleotide sequences and conditions for PCR analyses
Primer Sequence Amplicon size (bp) Annealing temperature (°C)
CCNA1metF TTTCGAGGATTTCGCGTCGT 46 53
CCNA1metR CTCCTAAAAACCCTAACTCGA
CCNA1unmetF TTAGTGTGGGTAGGGTGTT 67 53
CCNA1unmetR CCCTAACTCAAAAAAACAACACA
CCNA1cloningF TGGGTAGGGCGTCGTAGTT 196 55
CCNA1cloningR GCCCCCGACCTAAAAAAA
CCNA1cDNAF ATTCATTAAGTGAAATTGTGC 170 47
CCNA1cDNAR CTTCCATTCAGAAACTTATTG
GAPDHF GTGGGCAAGGTATCCCTG 460 52
GAPDHR GATTCAGTGTGGTGGGGGACBMC Cancer 2006, 6:55 http://www.biomedcentral.com/1471-2407/6/55
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CCNA1 methylation in CC cell lines
Duplex MSP for CCNA1 was designed according to the
sequence in Figure 1A. The methylated sequence com-
prised of 46 bp and the non-methylated sequence, 67 bp,
shown as the lower and the upper amplicons, respectively.
Previously, Carsten Müller-Tidow et al. [26,27] exten-
sively studied the role of CCNA1 methylation and found
that  CCNA1  was methylated in several non-expressing
tumor cell lines, including HeLa. To confirm this particu-
lar finding in CC cell lines, we investigated methylation
and expression in HeLa and SiHa cells. Our preliminary
study in HeLa, HeLa(S), revealed complete non-methyla-
tion, which contradicts the previous report (Fig. 1B). To
settle this controversy, we attempted to further evaluate
additional CC cell lines, including HeLa(K) grown in a
different laboratory, and SiHa. The result confirmed the
Carsten Müller-Tidow et al. [26,27] finding, in that the
majority of Hela(K) cells, as well as all SiHa cells, were
hypermethylated. CCNA1 RT-PCR confirmed the inverse
relation between DNA methylation and gene expression.
CCNA1 RNA levels were high, intermediate and low in
HeLa(S), HeLa(K) and SiHa cells, respectively (Fig. 1).
These data indicate that CCNA1 methylation is common
in CC cell lines and its physiological role is to decrease
gene expression. The absence of methylation in HeLa(S)
might indicate a demethylation process that occurs under
different cell culture and maintenance conditions.
We validated the reliability of this duplex MSP by per-
forming calibration experiments using SiHa mixed with
HeLa(S), CCNA1 completely hypermethylated and non-
methylated cells, respectively (Fig. 2A). With at least three
replicates for each experiment, the result demonstrates the
consistency of the current approach, with minimal intra-
and inter-assay variations (Fig. 2B). It is noteworthy that
the correlation between measured and actual CCNA1
methylation percentages was not linear, but exponential.
CCNA1 methylation and expression in cervical tissues
The discovery of an inverse correlation between CCNA1
methylation and expression in CC lines suggested possi-
bility of the same situation in vivo. To test this hypothesis,
we evaluated the epigenetic control in vivo. Six frozen
OTC-embedded CCs and five normal cervices were micro-
dissected and subjected to duplex MSP and CCNA1 RT-
PCR. Figure 3 shows examples of typical in vivo results.
First, whereas no methylation could be observed, CCNA1
mRNA was discoverable by RT-PCR in normal cervix from
both epithelium and connective tissue cells (Fig. 3A). In
contrast, epigenetic control was detectable in cervical epi-
thelia of CC patients from both malignant cells and adja-
cent histologically normal cervical epithelia. Nonetheless,
in matched cases, a higher degree of methylation could be
demonstrated in cancer than in normal cells. From all
CCs, no CCNA1 mRNA was detectable. Interestingly, even
if methylation was detected, CCNA1 was expressed in
malignancy-adjacent histologically normal cervical tis-
sues. Moreover, an inverse correlation between the meth-
ylation level and mRNA quantity was observed. CCNA1
expression in methylated malignancy-adjacent histologi-
cally normal cervical epithelium may be due to normal
cell contamination or partial methylation at the promoter
according to CC multistep progression. Whereas complete
methylation could be observed in most cancer cells, par-
tial and non-methylated CCNA1 was discovered in the
adjacent epithelia (Fig. 3B). In conclusion, this experi-
ment evaluating cervical tissue in vivo led to three conclu-
sions. First, CCNA1  methylation was exclusively
associated with cervical carcinogenesis. Second, the epige-
netic alteration occurred earlier than morphological trans-
formation of the cellular phenotype. Finally, methylation
may play a role in this gene inactivation.
Schematic representation of inverse correlation between  promoter methylation and expression of CCNA1 in CC cell  lines Figure 1
Schematic representation of inverse correlation between 
promoter methylation and expression of CCNA1 in CC cell 
lines. (A) Diagram of methylated and non-methylated 
sequences after bisulfite modification covering the area of 
both primers (underlined) in the promoter region of CCNA1. 
M, DNA size marker. Top panel, 10-bp ladder; bottom four 
panels, 100-bp ladder. Neg, negative. (B) Duplex MSP analysis 
of cell lines. Upper and lower arrows indicate non-methyl-
ated and methylated amplicons, respectively. MSP, methyla-
tion-specific PCR. (C-E) RT-PCR of the CCNA1 gene after 28, 
30 and 35 cycles, respectively. (F) RT-PCR of the GAPDH 
gene as an internal control.BMC Cancer 2006, 6:55 http://www.biomedcentral.com/1471-2407/6/55
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CCNA1 methylation incidence during multistep cervical 
carcinogenesis
Cervical intraepithelial neoplasia provides a crucial model
to study the multistep process of carcinogenesis. There-
fore, we evaluated the frequency of CCNA1 methylation
in several cervical epithelial tissues with a distinctive
degree of malignant transformation, normal cervix, CIN,
microinvasive and CC, respectively. We selected 43, 25
and 30 cases of white blood cells (WBC), normal cervical
biopsies and invasive CCs, respectively (Table 2). Among
these samples, 13 WBC samples and 6 normal cervical
samples, located at least 3 cm from the tumor margin and
showing the absence of HPV DNA, originated from CC
patients. For all cases, when a methylated amplicon was
visible and the methylation percentage measured
exceeded 5%, the test was deemed positive. All selected
CCs were squamous and positive for HPV. Of the cases, 24
harbored HPV type 16, 4 had HPV type 18 and 2 cases dis-
played unclassifiable HPV types. Interestingly, a high fre-
quency of methylation was exclusively present in CCs, i.e.,
28 cases or 93.3% (Fig. 4A,B and Table 2). To reveal mul-
tistep carcinogenesis, we included 24 cases of SILs and 5
microinvasive cancers from exfoliated cervical cells. All
cases were positive for oncogenic HPV, analyzed by
Hybrid Capture 2. Whereas 60% and 36.6% of the micro-
invasive cancers and high SILs, respectively, demonstrated
CCNA1 methylation, none of the HPV-associated low SILs
exhibited these epigenetic changes (Fig. 4B and Table 2).
Discussion
This study demonstrated that: (i) CCNA1 promoter hyper-
methylation in HPV-associated squamous cell CC is unu-
sually common; (ii) it is specific to CC; and (iii) the
methylation is more common in invasive phenotypes
compared to other histopathological stages during multi-
step carcinogenesis. This finding identifies both the inter-
esting biology of CC and a potential clinical application
of CCNA1 methylation as an additional molecular marker
for the early diagnosis of invasive CC.
Annual cytology screening has dramatically increased the
effectiveness of early CC detection. Nonetheless, addi-
tional tests will help to improve the sensitivity and specif-
icity of a single Papanicolaou smear for histological
Intra- and inter-assay variation of the duplex MSP Figure 2
Intra- and inter-assay variation of the duplex MSP. (A) Duplex MSP of a mixture of CCNA1 complete and non-methylated CC 
cell lines, SiHa and HeLa(S), respectively. M, DNA size marker; Neg, negative; 0, 25, 50, 75, 100 Met (%) represent the propor-
tion of SiHa DNA in the mixture, varied from 0 to 100%, respectively. The upper and lower bands are non-methylated and 
methylated bands, respectively, indicated by labeled arrows. (B) Graphical comparison between measured CCNA1 methylation, 
percentage intensity of methylation amplicon (x-axis), and actual methylation, the proportion of SiHa DNA (y-axis). The bar 
height indicates the mean and error bars, T, represent standard deviation (SD) across experiments.BMC Cancer 2006, 6:55 http://www.biomedcentral.com/1471-2407/6/55
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analysis. Recently, testing for oncogenic HPVs has been
introduced to aid in the triage of women with atypical
squamous cells of undetermined significance (ASCUS).
[28] However, because the majority of patients with HPV-
associated lesions do not progress to invasive cancer, sev-
eral studies have attempted to add a panel of tumor sup-
pressor gene methylations to improve the effectiveness of
molecular cytological diagnosis. [29,30] Since the fre-
quency of CCNA1  methylation is high and specific to
invasive CC, this gene should be a good candidate to
increase the coverage rate for early cancer detection.
In HNSCC, CCNA1  promoter hypermethylation is
inversely related to TP53 mutation. [13] Nonetheless, the
frequency of CCNA1 promoter hypermethylation in CC is
high, whereas the function of TP53 in CC is usually
impaired as a consequence of protein degradation
induced by binding of the viral E6 protein. [18] This
observation may be due to either differences in tissue
types or pathophysiological outcomes of TP53 between
mutations and diminution of the protein function subse-
quent to E6 binding. We prefer the latter hypothesis, since
TP53  and  CCNA1  have been shown to augment each
CCNA1 methylation and expression in microdissected cervical tissues Figure 3
CCNA1 methylation and expression in microdissected cervical tissues. (A) Duplex MSP and CCNA1 PCR; E and CNT are epithe-
lium and connective tissue cells from normal cervix; N and T are adjacent histological normal and cancer cervical epithelium 
from CC, respectively. Arrows indicate non-methylated, methylated, CCNA1 cDNA and GAPDH cDNA, respectively. (B) 
Bisulfite sequencing at the CCNA1 promoter, with circles denoting the methylation status of each selected clone. Black and 
white circles are methylated CG dinucleotides, and non-methylated CpG dinucleotides and TG dinucleotides, respectively.BMC Cancer 2006, 6:55 http://www.biomedcentral.com/1471-2407/6/55
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other's expression. [13,14] Consequently, the CCNA1
protein could help to increase physiologic TP53 to coun-
ter the function of E6, except for cases of TP53 mutation.
In other words, alterations of both CCNA1 and TP53 in
HNSCC will be redundant. In contrast, in CC, a decrease
in CCNA1 protein should prevent the increment of TP53
that would have compensated for the protein destruction
by E6.
Multistep process analysis revealed that CCNA1 methyla-
tion is remarkably specific for cervical carcinogenesis. The
biological function of CCNA1 is to activate DNA breakage
repair by mechanisms depending on CDK2 activity and
Ku proteins. [14] It is interesting to hypothesize why the
genomic instability, triggered by impairment of the
CCNA1 function, is crucial as an early event in CC devel-
opment. Perhaps the rate of spontaneous mutations in
cervical epithelial cells is too low to accumulate sufficient
malignancy-transformation-dependent oncogene and
Table 2: CCNA1 methylation and clinico-pathological correlation
Histological characteristics Total number of cases CCNA1 promoter hypermethylation
Absent Present
WBC 43 43 0
Normal cervix 25 25 0
Low-grade SIL 13 13 0
High-grade SIL 11 7 4
Microinvasive cancer 5 2 3
Squamous cell CC 30 2 28
FIGO stage I-IIA 6 0 6
FIGO stage IIB-IV 24 2 22
Grade 1, keratinized type 9 0 9
Grade 2, non-keratinized type 21 2 19
FIGO, International Federation of Gynecology and Obstetrics.
Schematic representation of methylation-specific PCR in CC Figure 4
Schematic representation of methylation-specific PCR in CC. (A) PCR analysis of CC: M, DNA size marker; Neg, water; N and 
T, matched normal cervices and tumors, respectively. (B) Bar graph demonstrating the frequency of DNA methylation. Num-
bers on the y-axis are the percentage of positive methylation cases. Sample types are on the x-axis. WBC, normal cervix, Low-
grade SIL, High-grade SIL, microinvasive cancer and squamous cell CCs number are 43, 25, 13, 11, 5, and 30, respectively. The 
methylation frequencies of each tissue type are represented by the height of each rectangular bar. BMC Cancer 2006, 6:55 http://www.biomedcentral.com/1471-2407/6/55
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tumor suppressor gene mutations if the cells possess fully
functional CCNA1. Therefore, the frequency of invasive
CC devoid of CCNA1 methylation is limited.
Conclusion
This study demonstrates the strong association between
CCNA1 promoter hypermethylation and invasive HPV-
associated CC indicates that this gene could serve as an
effective molecular marker. Moreover, our finding, in
comparison with previous reports, [13,14] also suggests
that there is a possible molecular link between oncogenic
HPVs, TP53 and CCNA1 promoter hypermethylation.
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